Inhibikase Therapeutics Appoints Mark Iwicki as New CEO

Inhibikase Therapeutics ( (IKT) ) has issued an announcement.

Inhibikase Therapeutics announced the resignation of Milton H. Werner as CEO and the appointment of Mark Iwicki, effective February 14, 2025. Werner’s departure was amicable, with a consulting agreement extending his service. Iwicki, a seasoned biopharmaceutical executive, brings extensive experience and is expected to advance the company’s lead product, IkT-001Pro, enhancing Inhibikase’s positioning in the cardiopulmonary therapeutic market. Additionally, Amit Munshi has been appointed as the new Chair of the Board, reflecting a strategic leadership shift aimed at driving growth and fulfilling unmet needs in PAH treatment.

More about Inhibikase Therapeutics

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary diseases. Its lead product, IkT-001Pro, is a prodrug of imatinib mesylate for pulmonary arterial hypertension (PAH), designed to offer an improved patient experience with fewer side effects.

YTD Price Performance: -28.57%

Average Trading Volume: 276,973

Technical Sentiment Consensus Rating: Hold

Current Market Cap: $163M

For an in-depth examination of IKT stock, go to TipRanks’ Stock Analysis page.